The prevalent cases of Dup15q syndrome vary worldwide, IN the USA it ranges from 23 to 29 cases per 100,000 and approximately 25 to 31 cases per 100,000 population in Europe. Germany is the leading country among the EU region in terms of total diagnosed and prevalent cases of Dup15q syndrome. Dup15q syndrome appears to be a rare disease reported globally.
Dup15q Syndrome – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Comprehensive insight on patient segmentation based on age, sex, Genotype, phenotype, Signs & Symptoms, associated conditions (r intellectual disability (ID), autism spectrum disorder (ASD), delayed development, and epilepsy, etc), severity (Mild, Moderate & Severe) has been provided into the epidemiology (Incidence and Prevalence) section of the Dup15q Syndrome and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
In terms of pharmacologic therapies, only one drug candidate is under Phase-II stages of development. Key assets among these are, TAK-935; Ovid Therapeutics Inc. one of the assets is being designated as an orphan drug from EMA. The launch of key assets will positively impact the overall market from 2018 to 2030 in 8 MM countries. The open-label Phase 2 CADE is a Phase 2, multi-center, open-label, pilot study that will evaluate the treatment of OV935 in pediatric patients, aged 2 to 17 years old, with epileptic seizures associated with CDD or Dup15q syndrome. The primary endpoint is the change in motor seizure frequency in patients treated with OV935 by disorder (CDD and Dup15q). The key secondary endpoints include safety and tolerability, including the percentage of participants considered treatment responders, change in CGI-S/C, and correlation of OV935 concentration and plasma 24HC levels.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Leptomeningeal Metastases (LM) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Wiskott–Aldrich Syndrome – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Adenosine deaminase deficiency – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Metachromatic Leukodystrophy – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Pustular Psoriasis – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,
PR-Wirein, Reportedtimes, iCN Internal Distribution, Research Newswire, English